Enhancing gut microbiota reduces spinal cord injury pneumonia risk via gut-lung interactions

Research Hypothesis:
Our research hypothesis was that enhancing the gut microbiota after spinal cord injury (SCI) could reduce the risk of pneumonia by modulating the gut-lung axis. We posited that probiotic supplementation could rebalance gut microbiota, thereby mitigating lung microbiota dysbiosis and decreasing the incidence of pneumonia in SCI patients.

Data Collection and Analysis:
To test our hypothesis, we conducted a series of controlled experiments using both human and mouse models. For the human study, we collected data from patients with SCI at Huashan Hospital, tracking incidences of pneumonia and analyzing gut and lung microbiota compositions through high-throughput sequencing of bacterial 16S rRNA genes. In our mouse model, SCI was surgically induced, followed by administration of specific probiotics. We monitored changes in the microbiota, the occurrence of pneumonia, and immune responses over time.

Notable Findings:

Gut-Lung Microbiota Similarity: Post-SCI, there was a significant increase in the similarity between gut and lung microbiota in both humans and mice, suggesting potential microbial translocation between these sites.
Probiotic Supplementation: Supplementation with Bifidobacterium and Akkermansia in mice led to a marked improvement in the diversity and stability of gut microbiota. This change was associated with reduced lung microbiota dysbiosis and lower inflammation levels in the lungs.
Reduction in Pneumonia Incidence: In the human cohort, SCI patients who received probiotic supplementation showed a statistically significant reduction in pneumonia incidence compared to those who did not receive probiotics.
Interpretation of Data:
The data supports the hypothesis that gut microbiota modulation has a protective effect against pneumonia post-SCI, likely mediated through the gut-lung axis. The observed increase in microbiota similarity between the gut and lungs post-SCI suggests that microbial translocation could be a contributing factor to lung infections. Probiotic supplementation appears to stabilize gut microbiota, which in turn may help to maintain lung microbiota balance and immune function, thereby reducing the risk of pneumonia.

Usage of Data:
This data can be utilized to further explore the therapeutic potential of targeting the gut microbiota in SCI patients to prevent secondary infections such as pneumonia. The findings also suggest broader applications in managing pulmonary infections by modulating gut microbiota in other patient populations susceptible to dysbiosis and immune suppression. Further research should investigate the specific mechanisms of microbial translocation and the role of individual microbial species in promoting lung health post-injury.

研究假设：本研究假设，在脊髓损伤（SCI）后增强肠道微生物群，可以通过调节肠道-肺轴来降低肺炎的风险。我们推测，通过补充益生菌可以重新平衡肠道微生物群，从而减轻肺微生物群失调，并降低SCI患者肺炎的发病率。
数据收集与分析：为验证我们的假设，我们使用人类和鼠类模型进行了一系列的对照实验。对于人类研究，我们从华山医院的SCI患者中收集数据，通过高通量测序细菌16S rRNA基因，追踪肺炎的发生率并分析肠道和肺微生物群的组成。在我们的鼠类模型中，通过手术诱导SCI，随后给予特定的益生菌。我们监测了微生物群的变化、肺炎的发生和免疫反应随时间的变化。
显著发现：肠道-肺微生物群相似性：在人类和鼠类中，SCI后肠道和肺微生物群之间的相似性显著增加，这表明这些部位可能存在潜在的微生物迁移。
益生菌补充：在鼠类中补充双歧杆菌和艾克曼氏菌导致肠道微生物群的多样性和稳定性显著提高。这种变化与肺微生物群失调的减轻和肺部炎症水平的降低相关。
肺炎发病率降低：在人类队列中，接受益生菌补充的SCI患者肺炎发病率与未接受益生菌的患者相比，显示出统计学上的显著降低。
数据解读：数据支持了肠道微生物群调节对SCI后肺炎具有保护作用的假设，这可能是通过肠道-肺轴介导的。SCI后肠道和肺之间微生物群相似性的增加表明，微生物迁移可能是导致肺部感染的一个贡献因素。益生菌补充似乎稳定了肠道微生物群，这反过来又可能有助于维持肺微生物群的平衡和免疫功能，从而降低肺炎的风险。
数据应用：这些数据可用于进一步探索针对SCI患者肠道微生物群的治疗潜力，以预防如肺炎等继发性感染。研究结果还表明，在易受菌群失调和免疫抑制的其他患者群体中调节肠道微生物群，在管理肺部感染方面具有更广泛的应用。未来的研究应调查微生物迁移的具体机制和个体微生物种在促进受伤后肺部健康中的作用。